The effectiveness of risperidone long-acting injection in oral antipsychotic non-adherent patients with schizophrenia: A retrospective study

Simple item page
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorSarandöl, Aslı
dc.contributor.buuauthorKotan, Vahap Ozan
dc.contributor.buuauthorCangür, Şengül
dc.contributor.buuauthorAydın, Ayşegül
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid35096351000tr_TR
dc.contributor.scopusid8604063700tr_TR
dc.contributor.scopusid15059926700tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.date.accessioned2022-03-25T08:10:19Z
dc.date.available2022-03-25T08:10:19Z
dc.date.issued2009-09
dc.description.abstractObjective: To determine effectiveness and adherence to risperidone long-acting injection (RLAI) in schizophrenic patients who were non-adherent to oral antipsychotic treatment. Method: We retrospectively checked over 30 schizophrenic patients (12 males, mean age=36.1 +/- 9.5 years) who were hospitalized for relapse of their disorder due to non-adherence to oral antipsychotic drugs. Assessment tools were Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Positive Symptoms (SAPS), Scale for Assessment of Negative Symptoms (SANS) and Simpson-Angus Scale (SAS). Mean follow-up was 236.1 +/- 121.0 (28-336) days. For 11 patients (36.7%), oral add-on antipsychotic treatment (OAT) was discontinued after the 3rd injection of risperidone (No-OAT group); for 19 (63.3%), it was continued (OAT group). Results: The proportion who discontinued medications was 46.7% overall; it was 45.5% for OAT and 47.4% for No-OAT groups (P=0.781). Mean BPRS, SAPS, SANS, and SAS scores decreased significantly from baseline during follow-up. The No-OAT group had a greater decrease (percent change in BPRS from baseline) than the OAT group at the 3(rd), 6(th), 9(th), 10(th), 11(th), 12(th), 13(th), 15(th) and 17(th) visits; for SANS, it was greater at the 6(th) and 10th visits (P<0.05 for both). The mean dose of RLAI was 46.9 +/- 6.7 mg, and this was similar for OAT and No-OAT groups (49 +/- 9.8 and 44 +/- 9.8, respectively, P = 0.292). Conclusions: In daily clinical practice, long-acting injectable risperidone is effective in schizophrenic patients, but oral antipsychotic drugs are frequently needed to be used together with RLAI in severe and chronic cases. RLAI had no additional effectiveness or adherence advantage in this study for patients with severe forms of schizophrenia.en_US
dc.identifier.citationAkkaya, C. vd. (2009). "The effectiveness of risperidone long-acting injection in oral antipsychotic non-adherent patients with schizophrenia: A retrospective study". Klinik Psikofarmakoloji Bülteni, 19(3), 255-262.tr_TR
dc.identifier.endpage262tr_TR
dc.identifier.issn1017-7833
dc.identifier.issue3tr_TR
dc.identifier.scopus2-s2.0-70350050076tr_TR
dc.identifier.startpage255tr_TR
dc.identifier.urihttp://hdl.handle.net/11452/25345
dc.identifier.volume19tr_TR
dc.identifier.wos000271692600008tr_TR
dc.indexed.scopusScopusen_US
dc.indexed.trdizinTrDizintr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherKüre İletişim Grubu A.Ştr_TR
dc.relation.journalKlinik Psikofarmakoloji Bültenien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLong-acting risperidoneen_US
dc.subjectNon-complianceen_US
dc.subjectSchizophreniaen_US
dc.subjectStable patientsen_US
dc.subjectInjectable risperidoneen_US
dc.subjectPsychotic disordersen_US
dc.subjectDrugsen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectSymptomsen_US
dc.subjectPatternsen_US
dc.subjectTherapyen_US
dc.subjectTrialsen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subject.emtreeClozapineen_US
dc.subject.emtreeFlupentixolen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeLong acting drugen_US
dc.subject.emtreeNeuroleptic agenten_US
dc.subject.emtreeOlanzapineen_US
dc.subject.emtreePimozideen_US
dc.subject.emtreeQuetiapineen_US
dc.subject.emtreeRisperidoneen_US
dc.subject.emtreeZiprasidoneen_US
dc.subject.emtreeZuclopenthixolen_US
dc.subject.emtreeAdd on therapyen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBrief Psychiatric Rating Scaleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical assessment toolten_US
dc.subject.emtreeClinical practiceen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeDrug withdrawalen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInjectionen_US
dc.subject.emtreeInjection site painen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreePatient complianceen_US
dc.subject.emtreePositive and negative syndrome scaleen_US
dc.subject.emtreeRelapseen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSchizophreniaen_US
dc.subject.emtreeSimpson angus scaleen_US
dc.subject.emtreeStatistical significanceen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.scopusInjection; Aripiprazole Lauroxil; Neuroleptic Agenten_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleThe effectiveness of risperidone long-acting injection in oral antipsychotic non-adherent patients with schizophrenia: A retrospective studyen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Akkaya_vd_2009.pdf
Size:
150.61 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus